Taken together, these results indicate that TRIM47 conferred Olaparib sensitive of triple-negative breast cancer and BRCA1 inhibits TRIM47 overexpression induced Olaparib sensitive both in vitro and in vivo. The gene discussed is BRCA1; the disease is triple-negative breast carcinoma.